

**Metabolic-Associated Fatty Liver Disease is Associated with Colorectal Adenomas in
Young and Older Korean Adults**

Jiwon Chang,¹ Yoosoo Chang,^{2,3,4*} Yoosun Cho,^{1,2} Hyun-Suk Jung,^{1,4} Dong-Il Park,⁵ Soo-
Kyung Park,⁵ Soo-Youn Ham,⁶ Sarah H. Wild,⁷ Christopher D. Byrne,^{8,9} and Seungho
Ryu^{2,3,4*}

¹Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of
Medicine, Seoul, Republic of Korea

²Center for Cohort Studies, Kangbuk Samsung Hospital, Sungkyunkwan University School of
Medicine, Seoul, Republic of Korea

³Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital,
Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

⁴Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for
Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea

⁵Division of Gastroenterology, Department of Medicine, School of Medicine, Kangbuk
Samsung Hospital, Sungkyunkwan University, Seoul, Republic of Korea

⁶Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of
Medicine, Seoul, Republic of Korea

⁷Usher Institute, University of Edinburgh, Edinburgh, UK

⁸Nutrition and Metabolism, Faculty of Medicine, University of Southampton, Southampton,
UK

⁹National Institute for Health and Care Research Southampton Biomedical Research Centre,
University Hospital Southampton, Southampton, UK

*** Corresponding author**

Seungho Ryu, MD, PhD,

Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital,
Sungkyunkwan University School of Medicine, Samsung Main Building B2, 250 Taepyung-
ro 2ga, Jung-gu, Seoul 04514, Republic of Korea

Tel.: +82-2-2001-5137

Fax : +82-2-757-0436

Email : sh703.yoo@gmail.com

Yoosoo Chang, MD, PhD,

Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital,
Sungkyunkwan University School of Medicine, Samsung Main Building B2, 250 Taepyung-
ro 2ga, Jung-gu, Seoul 04514, Republic of Korea

Tel.: +82-2-2001-5139

Fax: +82-2-757-0436

Email: yoosoo.chang@gmail.com

Word count: abstract 250 words, **text** 4,453 words

Figure number: 1, **Table** number: 4 (Supplementary table number: 3)

Abbreviations:

BMI : body mass index

BP : blood pressure

CI: Confidence intervals

1 CRA : colorectal adenoma

2 CRC : colorectal cancer

3 HbA1c: Glycated hemoglobin

4 HOMA-IR : homeostatic model assessment for of the insulin resistance

5 HR: Hazard ratios

6 hs-CRP: High-sensitivity C-reactive protein

7 MAFLD : metabolic dysfunction-associated fatty liver disease

8 NAFLD : non-alcoholic fatty liver disease

9
10 **Conflict of interest statement:** The authors declare that they have no competing interests.

11
12 **Acknowledgement:** We extend our sincere gratitude to the dedicated staff members of the
13 Kangbuk Samsung Health Study for their unwavering commitment, diligent efforts, and
14 invaluable support.

15
16 **Data availability statement:** The data are not publicly available because of institutional
17 review board restrictions (the data were not collected in a manner that could be widely
18 distributed). However, the analytical codes are available from the corresponding author upon
19 request.

20 **Funding statement.** This study was supported by the SKKU Excellence in Research Award
21 Research Fund, Sungkyunkwan University (2021), and by the National Research Foundation
22 of Korea, funded by the Ministry of Science, ICT, and Future Planning (NRF-
23 2021R1A2C1012626). CDB is supported in part by the Southampton National Institute for
24 Health and Care Research Biomedical Research Centre NIHR *grant code*, NIHR203319.

Abstract

Background & Aims: Given that the majority of colorectal cancers (CRCs) develop from high-risk adenomas, identifying risk factors for high-risk adenomas is important. The relationship between metabolic dysfunction-associated fatty liver disease (MAFLD) and the risk of colorectal adenoma in young adults remains unclear. We aimed to evaluate this relationship in adults <50 (younger) and ≥ 50 (older) years of age.

Methods: This cross-sectional study included 184,792 Korean adults (80% <50 years of age) who all underwent liver ultrasound and colonoscopy. Participants were grouped into those with and without MAFLD and classified by adenoma presence into no adenoma, low-risk adenoma, or high-risk adenoma (defined as ≥ 3 adenomas, any ≥ 10 mm, or adenoma with high-grade dysplasia/villous features).

Results: The prevalence of low- and high-risk adenomas among young and older adults was 9.6% and 0.8% and 22.3% and 4.8%, respectively. MAFLD was associated with an increased prevalence of low- and high-risk adenomas in young and older adults. Young adults with MAFLD had a 1.30 (95% CIs 1.26–1.35) and 1.40 (1.23–1.59) times higher prevalence of low- and high-risk adenomas, respectively, compared to those without MAFLD. These associations were consistent even in lean adults ($\text{BMI} < 23 \text{ kg/m}^2$) and those without a family history of colorectal cancer.

Conclusion: MAFLD is associated with an increased prevalence of low- and high-risk adenomas in Korean adults, regardless of age or obesity status. Whether reducing metabolic risk factors, such as MAFLD, reduces the risk of precancerous lesions and ultimately reduces the risk of early-onset CRC requires further investigation.

Keywords: Metabolic Dysfunction-Associated Fatty Liver Disease; Obesity; Young-Onset

Colorectal Adenoma.

Lay Summary

The incidence of early-onset CRC is rising, and the most of colorectal cancers develop from high-risk adenomas. The relationship between MAFLD and the risk of colorectal adenoma in young adults was unclear until this study. In this large cohort of Korean adults undergoing colonoscopy, MAFLD is associated with an increased prevalence of low- and high-risk colorectal adenomas in young and older adults, regardless of sex, obesity status, and a family history of colon cancer.

1 **Introduction**

2 Despite an overall decrease in the global incidence of colorectal cancer (CRC),¹ the incidence
3 of early-onset CRC (<50 years) has increased.² The majority of CRCs develop from high-risk
4 adenomas. The annual transition rate from high-risk adenoma to CRC is estimated to be 2–
5 6%.³ Colorectal adenomas (CRAs) are classified as low- and high-risk adenomas, according
6 to size, degree of dysplasia, and the presence of a villous component.^{4–6} The detection and
7 removal of CRAs is likely to be the most effective strategy to prevent CRC.⁷ Risk factors
8 specific to young- or early-onset CRAs have not been well characterized, and adults aged <50
9 years are not routinely screened for CRC detection, which includes colonoscopy or fecal
10 blood tests. A better understanding of the risk factors for early-onset CRA/CRC is crucial for
11 developing screening strategies for young adults at risk of CRC.

12 Metabolic dysfunction-associated fatty liver disease (MAFLD) is being increasingly used to
13 redefine and reclassify non-alcoholic fatty liver disease (NAFLD), which commonly co-
14 occurs with metabolic syndrome.^{8,9} MAFLD affects approximately 25% of the global adult
15 population,¹⁰ and its increase among young adults is a cause for concern.¹¹ While studies
16 have explored the relationship between MAFLD/NAFLD and CRC,^{12–15} there are limited data
17 on the association between MAFLD and the risk of CRA in young adults. There is a strong
18 relationship between obesity and MAFLD; hence, MAFLD can also occur in lean adults, with
19 a prevalence of 4.1–34%.^{16,17} A recent study¹⁸ reported a stronger association between
20 MAFLD and CRA in non-obese adults than in obese adults. However, the clinical
21 implications of lean MAFLD on the development of CRC and its precursors remain unclear.

22 We aimed to examine the association between MAFLD and low- and high-risk adenomas in
23 young adults and to determine whether this association differs by sex and obesity.

1 **Methods**

2 We used retrospective deidentified data from the Kangbuk Samsung Health Study,¹⁹ a cohort
3 study of Korean adults that began in 2002. The Kangbuk Samsung Health Study mainly
4 comprises employees of companies or local government organizations and their spouses who
5 undergo routine health examinations every 1–2 years at Kangbuk Samsung Hospital, Seoul
6 and Suwon, South Korea.¹⁹ In this study, we focused on adults who underwent colonoscopy
7 as part of a comprehensive health screening program from 2015 (when a standardized report
8 was introduced for colonoscopy) to 2020. Under the Industrial Safety and Health Law in
9 Korea, employees are required to undergo annual or biannual health examinations. Most
10 participants were employees of companies or local government organizations and their
11 spouses. The remaining participants were registered individually for the program.

12 Participants with a history of CRC/inflammatory bowel disease/colorectal polyps, incomplete
13 colonoscopies, poor bowel preparations, or missing data on body mass index (BMI)/liver
14 ultrasound/alcohol consumption or history of colorectal polyp were excluded. Participants
15 who did not undergo biopsy for colorectal polyps owing to anticoagulant medication or
16 referral for polypectomy, with no data available on the results at the same hospital, were also
17 excluded (Figure 1). Because some participants met more than one exclusion criterion, the
18 final sample for analysis consisted of 184,792 participants.

19 This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital
20 (KBSMC 2023-03-005). The requirement for informed consent was waived owing to the use
21 of deidentified data collected during routine screening.

22 ***Measurements***

23 The health check-up program involved a standardized questionnaire survey and various

measurements, including physical examination, fasting blood measurements, transabdominal ultrasound, and other procedures, as described previously.²⁰ Average daily alcohol consumption was calculated from the frequency of alcohol consumption per week and the amount of alcohol consumed per drinking day. Physical activity was determined using the validated Korean version of the International Physical Activity Questionnaire–short form. A family history of colorectal cancer was defined as the presence of colon cancer in at least one first-degree relative at any age.

Trained nurses measured resting blood pressure (BP) and anthropometric parameters. Participants with a BMI ≥ 23 kg/m² (the cutoff for overweight/obesity in Asians)²¹ were classified as overweight/obese.

Blood samples were collected after ≥ 10 hours of fasting. Fasting serum measurements included lipid profiles and liver enzyme, glucose, high-sensitivity C-reactive protein (hs-CRP), and insulin levels. The Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index was calculated as fasting blood insulin (mU/mL) \times fasting blood glucose (mmol/L)/22.5. Diabetes was defined as fasting serum glucose ≥ 126 mg/dL (7 mmol/L), HbA1c $\geq 6.5\%$ (48 mmol/mol), or current use of insulin/glucose-lowering drugs.

Colonoscopic Examination and CRA Definition

Participants underwent colonoscopy that involved bowel preparation using 2 L of Coolprep® (Taejoon Pharmaceuticals Co. Ltd., Seoul, Korea), followed by insertion of an EVIS LUCERA CV-260 colonoscope (Olympus Medical Systems, Tokyo, Japan) from the rectum to the cecum by experienced gastroenterologists/general surgeons. Polypoid lesions were biopsied or removed and subsequently assessed by experienced pathologists.

Adenomas are classified according to their size, number, and histological features. High-risk

adenomas were defined as at least three adenomas, adenomas ≥ 10 mm, or adenomas with high-grade dysplasia/a villous component.⁴⁻⁶ Participants diagnosed with low- and high-risk adenomas were classified as high-risk.

MAFLD and Liver Fibrosis Assessment

Experienced radiologists, who were blinded to the study, conducted abdominal ultrasonography and diagnosed hepatic steatosis using standard criteria, including a diffuse increase in fine echoes in the liver parenchyma compared to those in the kidney or spleen parenchyma, deep beam attenuation, and bright vessel walls.^{20,22} Abdominal ultrasound was performed on the same day as that of the health examination, prior to colonoscopy. Fatty liver diagnosis showed substantial inter- and excellent intra-observer reliability (kappa statistic: 0.74 and 0.94, respectively).²⁰ MAFLD was defined as hepatic steatosis, detected by ultrasound and meeting metabolic criteria, including overweight/obesity (BMI ≥ 23 kg/m² in Asians), diabetes, or at least two metabolic abnormalities: (a) waist circumference ≥ 90 cm (men) or ≥ 80 cm (women), (b) BP $\geq 130/85$ mmHg or receiving BP-lowering drugs, (c) serum triglycerides ≥ 150 mg/dL or receiving specific treatment, (d) serum high-density lipoprotein < 40 mg/dL (men) or < 50 mg/dL (women), (e) prediabetes (fasting glucose 100–125 mg/dL [5.6–6.9 mmol/L] or HbA1c 5.7–6.4% [39–46 mmol/mol]), (f) HOMA-IR index ≥ 2.5 , or (g) hs-CRP > 2 mg/dL.⁹ Participants were categorized into two groups: those without MAFLD and those with MAFLD. Participants who had fatty liver but did not meet the criteria for MAFLD were classified as belonging to the no MAFLD group.

Hepatic steatosis was originally recorded as mild, moderate, or severe.²⁰ Mild hepatic steatosis was characterized by a slight increase in liver echogenicity. Moderate hepatic steatosis was identified by a mildly compromised visualization of the intrahepatic vasculature and diaphragm, coupled with increased liver echogenicity. Severe hepatic steatosis was indicated by a significant rise in liver echogenicity, hindered penetration of the posterior

segment of the right lobe, and inadequate or absent visualization of the intrahepatic vasculature and diaphragm.^{20,22} However, due to the limited number of cases with severe steatosis, these cases were combined with moderate steatosis. We also used the Fibrosis-4 (FIB-4) and NFS (NAFLD fibrosis score) score, validated non-invasive indices of advanced fibrosis, to evaluate HS severity.²³ The FIB-4 index was calculated for each of the subjects as $(\text{age} \times \text{AST (U/L)} / \text{platelet count } (\times 10^9/\text{L}) / \sqrt{\text{ALT (U/L)}})$ and was classified into low and intermediate/high groups based on 1.30 points. NFS was calculated as: $-1.675 + 0.037 \times \text{age (years)} + 0.094 \times \text{BMI (kg/m}^2) + 1.13 \times \text{IFG or diabetes (yes = 1, no = 0)} + 0.99 \times \text{AST/ALT ratio} - 0.013 \times \text{platelet } (\times 10^9/\text{l}) - 0.66 \times \text{albumin (g/dl)}$. The NFS cut-off points were defined as <-1.455 (low risk) and ≥ -1.455 (intermediate/high risk) for predicting probability of advanced fibrosis.²³

Statistical Analyses

Participants' characteristics are summarized according to MAFLD status. We evaluated the distribution of continuous variables, making the necessary adjustments. To examine the age-specific relationship between MAFLD and CRA, we conducted separate analyses of young and older adults. To estimate prevalence ratios and 95% confidence intervals (CIs) for low- and high-risk adenomas in adults with MAFLD compared to those without MAFLD, we used participants without adenomas as the reference group in the multinomial logistic regression analysis. The models were adjusted for age and sex and further adjusted for potential confounders (center, year of screening, smoking status, alcohol intake, educational level, a history of cardiovascular disease, and a family history of colon cancer). Subgroup analysis was performed to examine the associations between sex (male vs. female), overweight/obesity ($\text{BMI} \geq 23 \text{ kg/m}^2$) (yes vs. no), diabetes (yes vs. no), a family history of colorectal cancer (yes vs. no) and number of metabolic abnormalities (<2 or vs. ≥ 2).

1 Additionally, we conducted sensitivity analyses to investigate the presence of a dose-response
2 relationship between MAFLD with a low probability of advanced fibrosis and MAFLD with
3 an intermediate/high probability of advanced fibrosis (indicated by a low fibrosis score versus
4 an intermediate and high fibrosis score for both FIB-4 and NFS scores), and the prevalence of
5 low- and high-risk CRA. Likelihood ratio tests were used to compare models with and
6 without multiplicative interaction terms. All statistical analyses were conducted using Stata
7 (version 17.0; StataCorp LP, College Station, TX, USA). Significance was set at a two-tailed
8 $P < 0.05$.

10 **Results**

11 The mean (standard deviation) age of the 184,792 participants was 42.6 (9.4) years, with
12 80.4% of participants aged <50 years (Table 1). Young and older adults with MAFLD were
13 more likely to be male and had a higher prevalence of diabetes, hypertension, and lipid-
14 lowering medication use. They were also more likely to have unhealthy metabolic profiles
15 and higher liver enzymes and were less likely to be physically active.

16 Table 2 presents the prevalence of low- and high-risk adenomas, according to the presence of
17 MAFLD, in young and older adults. In young adults, the prevalence of low- and high-risk
18 adenomas was 9.6% and 0.8 %, respectively, whereas in older adults, the prevalence of low-
19 and high-risk adenomas was 22.3% and 4.8%, respectively. MAFLD was associated with an
20 increased prevalence of low- and high-risk adenomas in young and older adults, without a
21 significant interaction of age (P interaction = 0.464). After adjusting for potential
22 confounders, young adults with MAFLD had a 1.3 (95% CI: 1.26–1.35) times higher
23 prevalence of low-risk adenomas and a 1.4 (95% CI: 1.23–1.59) times higher prevalence of
24 high-risk adenomas compared to those without MAFLD. Similarly, in older adults, MAFLD

was associated with a 1.28 (95% CI: 1.21–1.34) and 1.53 (95% CI: 1.39–1.69) times higher prevalence of low- and high-risk adenomas, respectively.

The association between MAFLD and low- and high-risk adenomas in young and older adults did not differ by sex, overweight/obesity status, diabetes, two features of metabolic abnormalities, or a family history of colorectal cancer (Tables 3 and 4). A higher prevalence of adenomas in MAFLD was consistently observed even in lean adults (BMI <23 kg/m²) and those without diabetes or a family history of colon cancer.

Supplementary Tables 1 and 2 provides sensitivity analyses that employ noninvasive fibrosis markers to evaluate the impact of MAFLD severity. In young adults, the multivariable-adjusted prevalence ratios (PRs) with 95% confidence intervals (CIs) for low-risk CRA, comparing no MAFLD (reference) with low or intermediate/high NFS, were 1.29 (1.24–1.34) and 1.53 (1.38–1.71), respectively. In older adults, the corresponding PRs (95% CI) were 1.27 (1.20–1.35) and 1.28 (1.19–1.38). Similarly, for high-risk CRA, in young adults, the multivariable-adjusted PRs (95% CIs) comparing no MAFLD (reference) with low or intermediate/high NFS were 1.38 (1.21–1.57) and 1.64 (1.20–2.25), respectively. In older adults, the corresponding PRs were 1.59 (1.42–1.79) and 1.44 (1.26–1.65). The association between MAFLD severity based on NFS and CRA differed by age group, with a significant interaction (P for interaction=0.026). When using FIB-4 instead of NFS, the patterns were similar, but the interaction by age group was not statistically significant (P for interaction=0.184) (Supplementary Tables 1 and 2).

In sensitivity analysis using the degree of hepatic steatosis on ultrasonography (Supplementary Table 3), we observed that the prevalence of CRA increased with the degree of hepatic steatosis, showing a clear trend from no MAFLD to mild MAFLD and then to moderate-to-severe MAFLD in both young and older adults. Specifically, among young

adults, the multivariable-adjusted PRs (95% CI) for high-risk CRA, comparing no MAFLD (reference) with mild MAFLD or moderate-to-severe MAFLD, were 1.31 (1.14–1.50) and 1.79 (1.46–2.19), respectively. Similarly, in older adults, the corresponding PRs (95% CI) were 1.47 (1.32–1.63) and 2.00 (1.53–2.46), respectively.

Discussion

In this large study of young and older Korean adults who underwent colonoscopy as part of a comprehensive health screening program, we observed a positive association between MAFLD and the prevalence of low- and high-risk adenomas. This association was consistent across subgroups stratified by sex, obesity, and a family history of colorectal cancer. Our findings suggest that MAFLD (a hepatic phenotype with a metabolically unhealthy status) may play a role in the development of colorectal neoplasms and may help explain the recent increase in the incidence of early-onset CRC in young adults.

Earlier studies, including a systematic review,^{24–26} reported a moderate increase in the incidence and prevalence of CRA in patients with NAFLD. However, limited studies^{18,27} have investigated the relationship between MAFLD and CRA, especially early-onset CRA, with the distinction between low- and high-risk CRAs. A new definition of MAFLD was introduced in 2019,⁹ with an emphasis on the role of metabolic dysfunction in the pathogenesis of fatty liver disease. Our study, which included the largest number of participants among studies examining the relationship between MAFLD and CRA in young and older adults, supports the notion that MAFLD is an independent modifiable risk factor for low- and high-risk CRAs.

The incidence of early-onset CRC is increasing at an alarming rate worldwide,²⁸ with the prevalence of young-onset CRA estimated to be 4.2% before and 10.0% after 1995 (the year around which the incidence of early-onset CRC began to increase).²⁹ In our study, the

1 prevalence of young-onset CRA was 10.4%, even after excluding participants with a history
2 of colorectal polyps. This highlights the need for additional research in risk factors for early-
3 onset CRA. Risk factors for CRA in young adults have not been well characterized. Our
4 findings support the role of MAFLD as an independent risk factor for colorectal neoplasms,
5 regardless of age, and early-onset CRA as a metabolically driven neoplasm.

6 In the subgroup analysis, the association between MAFLD and CRA did not differ by sex.

7 The absolute prevalence of CRA was found to be lower in women compared to men,
8 consistent with previous study findings. Although the association between MAFLD and CRA
9 appeared to be stronger in young women than in young men, this difference was not
10 statistically significant (P for interaction = 0.720). Among young individuals without
11 MAFLD, women had the lowest prevalence of CRA, indicating a clear contrast with those
12 with MAFLD and resulting in stronger relative ratios than observed in men. Additionally,
13 other recent studies have shown that the presence of NAFLD or other metabolic
14 abnormalities reduced protection against cardiovascular diseases and type 2 diabetes in
15 premenopausal women.³⁰⁻³³ This may occur, at least in part, because hepatic fat represents
16 increased metabolic stress in premenopausal women, which could offset the protective effect
17 of estrogen.

18 The prevalence ratios of CRA were higher in the lean MAFLD group than in the obese
19 MAFLD group, even though the association between MAFLD and high-risk CRAs in young
20 adults was not significant, possibly owing to the small number of participants with high-risk
21 CRAs in this group. This finding is consistent with a previous study¹⁸ showing that non-obese
22 MAFLD is more strongly associated with CRA than obese MAFLD. However, the
23 mechanisms underlying the association between lean MAFLD and CRA remain unclear.
24 Evidence suggests that non-obese or lean MAFLD represents a distinct pathophysiological

entity with metabolic and histological profiles different from those of obese MAFLD.³⁴ Lean individuals, according to their BMI, are often classified as normal weight, despite having excess body fat or low muscle mass, based on a sophisticated body composition assessment.³⁵ They may even be classified as metabolically obese, based on further assessment of metabolic profiles, suggesting that lean NAFLD may be an unfavorable metabolic feature in BMI-based misclassified lean individuals. Lean NAFLD is also associated with adverse metabolic effects, such as increased visceral fat, insulin resistance, sarcopenia, and increased levels of proinflammatory cytokines,³⁶ which are associated with an increased risk of CRC and its precursors. Insulin resistance in NAFLD is closely associated with increased levels of insulin-like growth factor 1 and other growth factors,³⁷ which are associated with colon carcinogenesis and precancerous and cancerous lesions.³⁸ A higher prevalence of concomitant sarcopenia or specific gut microbiota profiles has been reported in lean MAFLD,³⁹ which are also associated with the pathogenesis of CRC.⁴⁰ Low muscle mass may be a feature of lean MAFLD, possibly in combination with excess abdominal adipose tissue, decreased protective adipose tissue, and low skeletal muscle mass. Finally, a polymorphism in Transmembrane 6 Superfamily Member 2 (a genetic determinant of lean MAFLD)³⁴ has been identified that is associated with CRA.⁴¹ Further research using detailed body composition measurements will improve our understanding of the role of lean MAFLD in early-onset CRA.

In this study, the risk of CRA tended to increase with the severity of fatty liver, which is consistent with previous research findings.^{27,42,43} Our study is first to demonstrate their association among young adults under the age of 50. Among these young adults, the prevalence of CRA increased with the severity of MAFLD, showing a trend from no MAFLD to MAFLD without advanced fibrosis and MAFLD with advanced fibrosis, particularly in high-risk CRA. The severity of MAFLD is closely related to the risk of colorectal tumors. This association may be attributed to factors such as an inflammatory state, insulin resistance,

1 decreased serum adiponectin levels, and intestinal bacterial overgrowth, which are more
2 common and severe as MAFLD progresses.⁴² Moreover, changes in bile acid patterns
3 associated with increasing fibrosis stages in patients with biopsy-proven NAFLD can alter the
4 composition of the gut microbiota and potentially contribute to colorectal neoplasm
5 development.^{44,45} It is worth noting that the natural course of MAFLD indicates that simple
6 steatosis takes an average of 15 years to progress to fibrosis.⁴⁶ Recently, there has been a
7 concerning increase in MAFLD cases among adolescents and even in childhood.¹¹
8 Consequently, young individuals with MAFLD and a high fibrosis score may have been
9 exposed to the disease for a significant period of time. However, the detailed information
10 about the onset and duration of MAFLD was not available in our study. Furthermore, in older
11 adults, the lack of clarity in the dose-response relationship between fibrosis and CRA could
12 be attributed to the exclusion of the history of colorectal polyps in our study, as past
13 colorectal polyp information was not available. As a result, older adults with a higher risk
14 profile might have been excluded from the study due to the exclusion of participants with a
15 history of colorectal polyps. On the other hand, the observed findings might better reflect the
16 lifetime prevalence of colorectal neoplasms in young adults, as they might have undergone
17 their first colonoscopy during the study. Further studies incorporating comprehensive data on
18 lifetime colorectal neoplasm, MAFLD onset and duration are warranted to enhance our
19 understanding of these relationships and potentially inform preventive measures and
20 treatment strategies for reducing colorectal tumor risk in these populations.

21 Our study has several limitations. First, fatty liver was diagnosed using sonography instead of
22 biopsy (the gold standard). However, ultrasonography is recommended as a first-line
23 investigation in the clinic due to its non-invasive nature and reasonable accuracy in
24 diagnosing fatty liver compared to histology.⁴⁷ According to a meta-analysis of observational
25 studies, conventional ultrasonography demonstrates a sensitivity of 82% and specificity of 80%

for detecting hepatic steatosis defined histologically as 5% or more steatotic hepatocytes.⁴⁷

Second, we obtained information about smoking and alcohol consumption, which are important confounders,⁴¹ based on a self-administered questionnaire, potentially leading to errors. Unmeasured factors, such as dietary information, may also have resulted in residual confounding. Third, the study population comprised relatively young and healthy individuals who underwent regular health examinations, limiting the generalizability of the results owing to the early detection and removal of precancerous lesions during screening colonoscopy. However, to minimize bias, we excluded participants with a history of colon polyps, as reported in the questionnaire completed before the examination. Fourth, due to the unavailability of detailed information on the exact size of the polyps as a continuous variable or their specific locations, we were not able to incorporate this extra detail into our study. Further research is necessary to explore whether the results differ based on the size and location of CRA. Finally, this study was conducted in Korea; hence, further research is needed to determine whether our results can be extended to other racial/ethnic groups.

The current CRC screening approach primarily relies on age and family history to determine the suitable time for initiating colonoscopy. However, the alarming increase in early-onset CRC cases necessitates a more comprehensive and precision medicine-oriented strategy to classify adults who could gain from earlier screening.⁴⁸ In our study, we demonstrated a significant association between MAFLD and an increased prevalence of colorectal adenomas, in both men and women, and even in lean individuals with a low BMI of <23 kg/m², and among young adults aged <50 years. Typically, the CRC risk tends to be underestimated in women, lean individuals, or young adults. MAFLD, as a condition defined by ectopic fat in the liver and an increased metabolic risk phenotype, should be considered a potential risk group within the relatively low-risk population, including young adults, thus warranting

1 consideration of potential earlier screening measures. Further research is required to establish
2 additional detailed conditions for identifying high-risk groups, particularly those under 50
3 years, who may benefit most from CRC screening.

4 In conclusion, MAFLD is associated with an increased prevalence of low- and high-risk
5 CRAs in young Korean adults. This association is consistent across subgroups stratified by
6 sex, obesity, and a family history of colon cancer. Given that CRAs in young adults may have
7 a metabolic origin, managing metabolic risk factors, such as MAFLD, may help prevent
8 early-onset CRC.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*. May 2021;71(3):209-249. doi:10.3322/caac.21660
2. Siegel RL, Torre LA, Soerjomataram I, et al. Global patterns and trends in colorectal cancer incidence in young adults. *Gut*. Dec 2019;68(12):2179-2185. doi:10.1136/gutjnl-2019-319511
3. Brenner H, Altenhofen L, Stock C, Hoffmeister M. Natural history of colorectal adenomas: birth cohort analysis among 3.6 million participants of screening colonoscopy. *Cancer Epidemiol Biomarkers Prev*. Jun 2013;22(6):1043-51. doi:10.1158/1055-9965.Epi-13-0162
4. Abu-Freha N, Katz LH, Kariv R, et al. Post-polypectomy surveillance colonoscopy: Comparison of the updated guidelines. *United European Gastroenterol J*. Jul 2021;9(6):681-687. doi:10.1002/ueg2.12106
5. Sekiguchi M, Matsuda T, Hotta K, Saito Y. Post-polypectomy surveillance: the present and the future. *Clin Endosc*. Jul 2022;55(4):489-495. doi:10.5946/ce.2022.097
6. Waldmann E, Kammerlander A, Gessl I, et al. New risk stratification after colorectal polypectomy reduces burden of surveillance without increasing mortality. *United European Gastroenterol J*. Oct 2021;9(8):947-954. doi:10.1002/ueg2.12119
7. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths. *New England Journal of Medicine*. Feb 23 2012;366(8):687-696. doi:10.1056/NEJMoa1100370
8. Lonardo A, Mantovani A, Lugari S, Targher G. NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. *International Journal of Molecular Sciences*. Jun 11

2019;20(11)doi:10.3390/ijms20112841

9. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *Journal of Hepatology*. Jul 2020;73(1):202-209. doi:10.1016/j.jhep.2020.03.039

10. Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*. Dec 2022;20(12):2809-2817.e28. doi:10.1016/j.cgh.2021.12.002

11. Zhang X, Wu M, Liu Z, et al. Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. *BMJ Open*. May 4 2021;11(5):e042843. doi:10.1136/bmjopen-2020-042843

12. Chen J, Bian D, Zang S, et al. The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies. *Expert Rev Gastroenterol Hepatol*. Apr 2019;13(4):385-395. doi:10.1080/17474124.2019.1580143

13. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. *Gut*. Apr 2022;71(4):778-788. doi:10.1136/gutjnl-2021-324191

14. Lonardo A, Roncucci L. The "obese liver" and gastrointestinal cancer risk. *Transl Gastroenterol Hepatol*. 2020;5:44. doi:10.21037/tgh.2019.12.07

15. Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. *J Hepatol*. Dec 2019;71(6):1229-1236. doi:10.1016/j.jhep.2019.08.018

16. DiStefano JK, Gerhard GS. NAFLD in normal weight individuals. *Diabetology & Metabolic Syndrome*. Mar 24 2022;14(1):45. doi:10.1186/s13098-022-00814-z

17. Ren TY, Fan JG. What are the clinical settings and outcomes of lean NAFLD? *Nat*

- 1 *Rev Gastroenterol Hepatol.* May 2021;18(5):289-290. doi:10.1038/s41575-021-00433-5
- 2 18. Fukunaga S, Nakano D, Kawaguchi T, et al. Non-Obese MAFLD Is Associated with
- 3 Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study.
- 4 *International Journal of Molecular Sciences.* May 22 2021;22(11)doi:10.3390/ijms22115462
- 5 19. Chang Y, Ryu S, Choi Y, et al. Metabolically Healthy Obesity and Development of
- 6 Chronic Kidney Disease: A Cohort Study. *Ann Intern Med.* Mar 1 2016;164(5):305-12.
- 7 doi:10.7326/M15-1323
- 8 20. Chang Y, Ryu S, Sung KC, et al. Alcoholic and non-alcoholic fatty liver disease and
- 9 associations with coronary artery calcification: evidence from the Kangbuk Samsung Health
- 10 Study. *Gut.* Sep 2019;68(9):1667-1675. doi:10.1136/gutjnl-2018-317666
- 11 21. WHO Western Pacific Region, IASO and IOTF. The Asia-Pacific Perspective:
- 12 Redefining Obesity and Its Treatment. Health Communications Australia Pty Limit: Sdney,
- 13 Australia. 2000;
- 14 22. Ballestri S, Nascimbeni F, Lugari S, Lonardo A, Francica G. A critical appraisal of
- 15 the use of ultrasound in hepatic steatosis. *Expert Rev Gastroenterol Hepatol.* Jul
- 16 2019;13(7):667-681. doi:10.1080/17474124.2019.1621164
- 17 23. Ballestri S, Mantovani A, Baldelli E, et al. Liver Fibrosis Biomarkers Accurately
- 18 Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in
- 19 Patients with NAFLD or Viral Chronic Liver Disease. *Diagnostics (Basel).* Jan 9
- 20 2021;11(1)doi:10.3390/diagnostics11010098
- 21 24. Mantovani A, Dauriz M, Byrne CD, et al. Association between nonalcoholic fatty
- 22 liver disease and colorectal tumours in asymptomatic adults undergoing screening
- 23 colonoscopy: a systematic review and meta-analysis. *Metabolism.* Oct 2018;87:1-12.
- 24 doi:10.1016/j.metabol.2018.06.004
- 25 25. Kim NH, Jung YS, Park JH, Park DI, Sohn CI. Impact of nonalcoholic fatty liver

disease on the risk of metachronous colorectal neoplasia after polypectomy. *Korean J Intern Med.* May 2021;36(3):557-567. doi:10.3904/kjim.2019.360

26. Alejandro V, Luis Antonio D, Eduardo F-L, et al. Colorectal adenomas and MAFLD: a cross-sectional study in a Hispanic screening cohort. *Colorectal adenomas and MAFLD: a cross-sectional study in a Hispanic screening cohort.* 2022;2(1):3. doi:10.20517/mtod.2021.17

27. Seo J-Y, Bae J-H, Kwak M-S, et al. The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease. *Biomedicines.* Oct 5 2021;9(10)doi:10.3390/biomedicines9101401

28. Akimoto N, Ugai T, Zhong R, et al. Rising incidence of early-onset colorectal cancer — a call to action. *Nature Reviews Clinical Oncology.* Apr 2020;18(4):230-243. doi:10.1038/s41571-020-00445-1

29. Enwerem N, Cho MY, Demb J, et al. Systematic Review of Prevalence, Risk Factors, and Risk for Metachronous Advanced Neoplasia in Patients With Young-Onset Colorectal Adenoma. *Clinical Gastroenterology and Hepatology.* Apr 2021;19(4):680-689.e12. doi:10.1016/j.cgh.2020.04.092

30. Lonardo A, Bellentani S, Argo CK, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.* Dec 2015;47(12):997-1006. doi:10.1016/j.dld.2015.08.004

31. Allen AM, Therneau TM, Mara KC, et al. Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease: A Longitudinal Cohort Study. *Am J Gastroenterol.* Nov 2019;114(11):1764-1771. doi:10.14309/ajg.0000000000000401

32. Yang JD, Abdelmalek MF, Guy CD, et al. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.

1 *Clinical gastroenterology and hepatology : the official clinical practice journal of the*
2 *American Gastroenterological Association.* Jan 2017;15(1):127-131.e2.
3 doi:10.1016/j.cgh.2016.07.034

4 33. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of
5 health, disease, and medicine. *Lancet.* Aug 22 2020;396(10250):565-582. doi:10.1016/S0140-
6 6736(20)31561-0

7 34. Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: A Distinct Entity Shaped by
8 Differential Metabolic Adaptation. *Hepatology.* Apr 2020;71(4):1213-1227.
9 doi:10.1002/hep.30908

10 35. Sommer I, Teufer B, Szelag M, et al. The performance of anthropometric tools to
11 determine obesity: a systematic review and meta-analysis. *Sci Rep.* Jul 29 2020;10(1):12699.
12 doi:10.1038/s41598-020-69498-7

13 36. Maier S, Wieland A, Cree-Green M, et al. Lean NAFLD: an underrecognized and
14 challenging disorder in medicine. *Rev Endocr Metab Disord.* Jun 2021;22(2):351-366.
15 doi:10.1007/s11154-020-09621-1

16 37. Dichtel LE, Cordoba-Chacon J, Kineman RD. Growth Hormone and Insulin-Like
17 Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease. *J Clin Endocrinol Metab.*
18 Jun 16 2022;107(7):1812-1824. doi:10.1210/clinem/dgac088

19 38. Kasprzak A. Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism
20 in Colorectal Cancer. *Int J Mol Sci.* Jun 16 2021;22(12)doi:10.3390/ijms22126434

21 39. Duarte SMB, Stefano JT, Miele L, et al. Gut microbiome composition in lean
22 patients with NASH is associated with liver damage independent of caloric intake:
23 A prospective pilot study. *Nutrition, Metabolism and Cardiovascular Diseases.* Apr
24 2018;28(4):369-384. doi:10.1016/j.numecd.2017.10.014

25 40. Kim M, Vogtmann E, Ahlquist DA, et al. Fecal Metabolomic Signatures in

Colorectal Adenoma Patients Are Associated with Gut Microbiota and Early Events of Colorectal Cancer Pathogenesis. *mBio*. Feb 18 2020;11(1)doi:10.1128/mBio.03186-19

41. Zhu JZ, Wang YM, Zhou QY, Zhu KF, Yu CH, Li YM. Systematic review with meta-analysis: alcohol consumption and the risk of colorectal adenoma. *Alimentary Pharmacology & Therapeutics*. Aug 2014;40(4):325-337. doi:10.1111/apt.12841

42. Zeng Y, Cao R, Tao Z, Gao Y. Association between the severity of metabolic dysfunction-associated fatty liver disease and the risk of colorectal neoplasm: a systematic review and meta-analysis. *Lipids Health Dis*. Jun 6 2022;21(1):52. doi:10.1186/s12944-022-01659-1

43. Blackett JW, Verna EC, Lebowitz B. Increased Prevalence of Colorectal Adenomas in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. *Dig Dis*. 2020;38(3):222-230. doi:10.1159/000502684

44. Caussy C, Hsu C, Singh S, et al. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. *Aliment Pharmacol Ther*. Jan 2019;49(2):183-193. doi:10.1111/apt.15035

45. Lonardo A, Singal AK, Osna N, Kharbanda KK. Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction. *Metab Target Organ Damage*. 2022;2(3)doi:10.20517/mtod.2022.14

46. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol*. Apr 2015;13(4):643-54.e1-9; quiz e39-40. doi:10.1016/j.cgh.2014.04.014

47. Ballestri S, Mantovani A, Byrne C, Lonardo A, Targher G. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of

1 observational studies. *Metabolism and Target Organ Damage*. 2021;1(7)

2 48. Amedeo L, Christopher DB, Giovanni T. Precision medicine approaches in metabolic
3 disorders and target organ damage: where are we now, and where are we going? *Precision*
4 *medicine approaches in metabolic disorders and target organ damage: where are we now,*
5 *and where are we going?* 2021;1(1):3. doi:10.20517/mtod.2021.03

6

7

1 **Figure legend**

2 Figure 1. Flow chart of the study population

3

4

5

6

7

8

9

10

11

12

13

14

15

16